Amarin to Present at Two Upcoming Investor Conferences

Mar 08, 2011, 16:30 ET from Amarin Corporation plc

MYSTIC, Conn. and DUBLIN, March 8, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in two upcoming investor conferences: the Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15, 2011 and the ROTH 23rd Annual OC Growth Stock Conference on Wednesday, March 16, 2011.

Paul Huff, Chief Commercial Officer, is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference on Tuesday, March 15 at 10:15 a.m. EDT. This conference will be held at the Loews Miami Hotel, Miami, Florida. A live audio webcast of the presentation will be available at: http://cc.talkpoint.com/barc002/031511a_rb/?entity=80_BL24705.

Declan Doogan, M.D., Chief Medical Officer, is scheduled to present at the ROTH 23rd Annual OC Growth Stock Conference on Wednesday, March 16 at 1 p.m. PDT. This conference will be held at the Ritz Carlton, Laguna Niguel, California. A live audio webcast of the presentation will be available at: http://www.wsw.com/webcast/roth24/amrn/.

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.

Investor Contact Information:

Stephen D. Schultz

Investor Relations and Corporate Communications

Amarin Corporation

In U.S.: +1 (860) 572-4979 x292

investor.relations@amarincorp.com

Lee M. Stern

The Trout Group

In U.S.: +1 (646) 378-2922

lstern@troutgroup.com

Media Contact Information:

David Schull or Martina Schwarzkopf, Ph.D.

Russo Partners

In U.S.:    +1 (212) 845-4271 or +1 (212) 845-4292 (office)

               +1 (347) 591-8785 (mobile)

david.schull@russopartnersllc.com

martina.schwarzkopf@russopartnersllc.com

SOURCE Amarin Corporation plc